Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025
Standard BioTools (NASDAQ: LAB) has announced its upcoming fourth quarter and full year 2024 earnings conference call, scheduled for February 26, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and operational progress.
Investors can join via phone using (888) 346-3970 for US domestic callers or (412) 902-4297 for international participants. A live webcast will be available on the company's Investor Relations page, with an archived version accessible afterward at investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) ha annunciato la sua prossima conferenza telefonica sui risultati finanziari del quarto trimestre e dell'intero anno 2024, programmata per 26 febbraio 2025, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica e un webcast alle 16:30 ET per discutere i risultati finanziari e i progressi operativi.
Gli investitori possono partecipare telefonicamente utilizzando il numero (888) 346-3970 per i chiamanti domestici negli Stati Uniti o (412) 902-4297 per i partecipanti internazionali. Un webcast dal vivo sarà disponibile sulla pagina delle Relazioni con gli Investitori dell'azienda, con una versione archiviata accessibile successivamente su investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) ha anunciado su próxima conferencia telefónica sobre los resultados financieros del cuarto trimestre y del año completo 2024, programada para el 26 de febrero de 2025, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica y un webcast a las 4:30 p.m. ET para discutir los resultados financieros y el progreso operativo.
Los inversores pueden unirse por teléfono utilizando el número (888) 346-3970 para los llamantes nacionales de EE. UU. o (412) 902-4297 para los participantes internacionales. Se podrá acceder a un webcast en vivo en la página de Relaciones con Inversores de la empresa, con una versión archivada disponible posteriormente en investors.standardbio.com.
스탠다드 바이오툴스 (NASDAQ: LAB)는 2024년 4분기 및 전체 연도 실적 컨퍼런스 콜을 2025년 2월 26일, 시장 마감 후에 진행한다고 발표했습니다. 회사는 오후 4시 30분 ET에 재무 결과 및 운영 진행 상황에 대해 논의하기 위해 컨퍼런스 콜 및 웹캐스트를 주최합니다.
투자자는 미국 내 전화(888) 346-3970 또는 국제 참가자를 위한 (412) 902-4297로 전화에 참여할 수 있습니다. 회사의 투자자 관계 페이지에서 실시간 웹캐스트를 이용할 수 있으며, 이후에 archived 버전은 investors.standardbio.com에서 접근할 수 있습니다.
Standard BioTools (NASDAQ: LAB) a annoncé sa prochaine conférence téléphonique sur les résultats financiers du quatrième trimestre et de l'année complète 2024, prévue pour le 26 février 2025, après la clôture des marchés. L'entreprise organisera une conférence téléphonique et un webcast à 16h30 ET pour discuter des résultats financiers et des avancées opérationnelles.
Les investisseurs peuvent rejoindre par téléphone en utilisant le (888) 346-3970 pour les appelants nationaux aux États-Unis ou (412) 902-4297 pour les participants internationaux. Un webcast en direct sera disponible sur la page des Relations avec les Investisseurs de l'entreprise, avec une version archivée accessible par la suite sur investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) hat seine bevorstehende Telefonkonferenz zu den Ergebnissen des vierten Quartals und des gesamten Jahres 2024 angekündigt, die für den 26. Februar 2025 nach Börsenschluss angesetzt ist. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz und ein Webcast abhalten, um die finanziellen Ergebnisse und den operativen Fortschritt zu besprechen.
Investoren können telefonisch teilnehmen, indem sie (888) 346-3970 für Anrufer aus den USA oder (412) 902-4297 für internationale Teilnehmer wählen. Ein Live-Webcast wird auf der Investor-Relations-Seite des Unternehmens verfügbar sein, mit einer archivierten Version, die danach unter investors.standardbio.com zugänglich ist.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.
Individuals can access the conference call by dialing:
US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297
Live audio of the webcast will be available online on the Investor Relations page of the Company’s website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
©2025 Standard BioTools Inc. All rights reserved.
Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
Investor Contact:
David Holmes
ir@standardbio.com
FAQ
When will Standard BioTools (LAB) release Q4 and FY 2024 earnings?
What time is Standard BioTools (LAB) Q4 2024 earnings call?
How can investors access Standard BioTools (LAB) Q4 2024 earnings call?
Where can I find the replay of Standard BioTools (LAB) Q4 2024 earnings call?
